Welcome to our dedicated page for Poolbeg Pharma PLC news (Ticker: $POLBF), a resource for investors and traders seeking the latest updates and insights on Poolbeg Pharma PLC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Poolbeg Pharma PLC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Poolbeg Pharma PLC's position in the market.
Rhea-AI Summary
Poolbeg Pharma announces a >$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS, supported by independent research. The company aims to focus on Rare and Orphan Diseases, leveraging the expertise of the former Amryt team. POLB 001 shows promise in addressing CRS induced by CAR-T and BsAb treatments, with potential cost-saving benefits and improved patient access to therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma announces promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced CRS. POLB 001 demonstrated efficacy in reducing CRS symptoms in an animal model, with potential market opportunity estimated at over US$1 billion. Independent Advisory Board supports POLB 001's potential as an oral therapy to address unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announces positive lab-based analysis and successful prioritization of RSV drug candidates, reflecting the high potential of its AI-led program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) presented key insights at the 65th American Society of Hematology Annual Meeting and Exposition regarding their potential therapy, POLB 001, for Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. The poster detailed positive results from the LPS human challenge trial, demonstrating good safety and tolerability, a clear dose-response relationship, and a reduction in pro-inflammatory cytokines. Phase II trial enabling activities are underway with strong interest from potential pharma partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (POLB) announces the resignation of Patrick Ashe, Independent Non-Executive Director, and the appointment of Eddie Gibson as Chair of the Audit & Risk Committee and Prof Brendan Buckley as Chair of the Remuneration Committee. The company is on an upward trajectory with a robust pipeline of high-value programs and aims to replicate the success of former Amryt Pharma plc leadership members recently appointed to the Poolbeg team. With strong financials, excellent clinical results, and productive partnering discussions, Poolbeg is well-positioned to generate significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (POLB) has received official decision from the Japanese Patent Office to grant Poolbeg's Immunomodulator II patent application, further strengthening the Company's robust intellectual property in the territory. Additionally, the fully granted patent for Immunomodulator I has been received from the Japanese Patent Office. Poolbeg has a worldwide license for POLB 001 for all uses in humans and is developing a strong IP portfolio with patents in place, covering the use of p38 MAP kinase inhibitors for the treatment of severe influenza and hypercytokinemia, as well as alongside cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma (POLB) announces the acceptance of an abstract highlighting the potential of POLB 001 as a groundbreaking therapy at the 18th International Congress of Immunology. POLB 001 is a potential treatment of severe influenza and Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. The poster presentation will discuss POLB 001's positive LPS human challenge trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announces the appointment of key former executives of Amryt Pharma plc to its leadership team. David Allmond, John McEvoy, and Laura Maher will join Poolbeg, enhancing the Company's expertise and capabilities. Allmond will become Chief Business Officer, McEvoy will be SVP, Chief Legal Officer, and Maher will assume the role of Vice President of Clinical Operations. The appointments aim to accelerate Poolbeg's strategy of developing exciting clinical assets and acquiring approved and marketed drugs to generate revenue and fund innovative product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma announces that an abstract detailing POLB 001's promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition. The presentation will provide insight into the results obtained from the POLB 001 LPS human challenge trial, highlighting its potential use in the treatment of CRS. An effective therapy for CRS associated with cancer immunotherapies has the potential to make these treatments more tolerable and widely accessible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) will host a meeting on November 6, 2023, to provide an update on its POLB 001 Oncology Programme. The program targets Cytokine Release Syndrome (CRS) associated with cancer immunotherapy treatments. Severe cases of CRS can be life-threatening, and an effective treatment could make these therapies more accessible and reduce side effects. The meeting will feature presentations from key opinion leaders and a patient advocate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Poolbeg Pharma PLC
OTC:POLBF
POLBF Rankings
POLBF Stock Data
61.74M
421.63M
21.5%
6.08%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
London